| Name | Title | Contact Details |
|---|
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.